埃克替尼联合全脑放疗治疗肺腺癌并脑转移的临床观察  

Clinical observation of icotinib combined with whole brain radiotherapy in the treatment of lung adenocarcinoma complicated with brain metastases

作　　者：赵善琳[1] 韦燕[1] 曾俊韶[1] 易海振 ZHAO Shan-lin;WEI Yan;ZENG Jun-shao(Department of Oncology, Guangxi Guigang City People’s Hospital, Guigang 537100, China)

机构地区：[1]广西贵港市人民医院肿瘤科,537100

出　　处：《中国现代药物应用》2017年第4期12-14,共3页Chinese Journal of Modern Drug Application

摘　　要：目的观察埃克替尼联合全脑放疗治疗肺腺癌并脑转移的临床效果。方法 40例肺腺癌并脑转移患者,根据患者意愿分为放疗组(全脑放疗)和联合组(埃克替尼联合全脑放疗),观察两组患者治疗后的效果,并评价比较两组患者治疗后的生活质量、不良反应及1、2年的生存率。结果联合组的临床获益率为95.00%,高于放疗组的70.00%,差异具有统计学意义(P<0.05)。放疗组的客观有效率为30.00%,低于联合组的75.00%,差异具有统计学意义(P<0.05)。联合组治疗后患者的5种功能状态(躯体功能、认知功能、情绪功能、角色功能和社会功能)评分分别与放疗组比较差异均具有统计学意义(P<0.05);且联合组患者总体生活质量评分高于放疗组,差异具有统计学意义(P<0.05)。联合组的不良反应总发生率为65.00%(13/20),高于放疗组的35.00%(7/20),但差异无统计学意义(P>0.05)。治疗结束2年后对患者随访发现,联合组患者中位生存时间为17.50个月,放疗组的中位生存时间为6.35个月,两组比较差异具有统计学意义(P<0.05);联合组患者1、2年生存率分别为55.00%(11/20)、30.00%(6/20),放疗组1、2年生存率分别为20.00%(4/20)、5%(1/20),两组比较差异均有统计学意义(P<0.05)。结论埃克替尼联合全脑放疗能够有效的治疗肺腺癌脑转移患者,显著提高患者的生活质量与生存期,且治疗后不良反应较小,对临床治疗肺腺癌脑转移具有参考意义,值得进一步研究推广。Objective To observe clinical effect by icotinib combined with whole brain radiotherapyin the treatment of lung adenocarcinoma complicated with brain metastases.Methods A total of40lungadenocarcinoma complicated with brain metastases patients were divided by patients’willingness into radiotherapygroup(whole brain radiotherapy)and combined group(icotinib combined with whole brain radiotherapy).Effectsafter treatment in both groups were observed.Evaluation and comparison were made on quality of life,adversereactions,1-year and2-year survival rates after treatment between the two groups.Results The combinedgroup had higher clinical benefit rate as95.00%than70.00%in the radiotherapy group,and their difference hadstatistical significance(P<0.05).The radiotherapy group had lower objective effective rate as30.00%than75.00%in the combined group,and the difference had statistical significance(P<0.05).The differences of5functionalstatus(physical function,cognitive function,emotional function,role function and social function)scores betweenthe combined group and the radiotherapy group all had statistical significance(P<0.05).The combined group hadoverall quality of life score than the radiotherapy group,and their difference had statistical significance(P<0.05).The combined group had higher incidence of adverse reactions as65.00%(13/20)than35.00%(7/20)in theradiotherapy group,while their difference had no statistical significance(P>0.05).Follow-up in2years aftertreatment showed that the combined group had median survival time as17.50months,which was6.35months inthe radiotherapy group,and their difference had statistical significance(P<0.05).The combined group had1-year and2-year survival rates respectively as55.00%(11/20)and30.00%(6/20),and the radiotherapy group had1-yearand2-year survival rates respectively as20.00%(4/20)and5.00%(1/20).The differences between the two groupsall had statistical significance(P<0.05).Conclusion Combination of icotinib and whole brain radiotherapyis effective in the treatment of lung adenocar

关 键 词：肺腺癌 埃克替尼 全脑放疗 脑转移 

分 类 号：R734.2[医药卫生—肿瘤]